Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
An open-label, non-comparative study conducted to investigate the activity and safety of
imatinib mesylate in refractory desmoplastic small round cell tumors expressing PDGF-R.
Patients will be treated up to 12 months, or to disease progression. Tumor will be evaluated
according to Recist criteria